FBIO (Fortress Biotech, Inc.) Bathi resik saben saham (EPS TTM)

Fortress Biotech, Inc. (FBIO) utilizes a network of external CDMO facilities for drug production, while current revenues are based on royalties from subsidiary entities. The current annual net income per share reflects profit dynamics, where the 2.32 mark characterizes this parameter. Business efficiency is further enhanced by digital capital management, which accelerates the delivery of innovative medicines to medical networks.

Long-term asset selection requires a thorough analysis of a business's ability to generate real income. This indicator calculates annual net income divided by the total number of shares, determining the earnings per share. For Fortress Biotech, Inc. (FBIO), this metric is critical due to high debt leverage and dependence on drug approvals by subsidiary entities. Negative values here reflect a venture cash deficit. By analyzing this chart of annual earnings per share, an investor assesses the holding company's pace toward reaching break-even.